<?xml version='1.0' encoding='utf-8'?>
<document id="26747099"><sentence text="Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB."><entity charOffset="31-42" id="DDI-PubMed.26747099.s1.e0" text="bedaquiline" /><entity charOffset="67-76" id="DDI-PubMed.26747099.s1.e1" text="lopinavir" /><entity charOffset="77-86" id="DDI-PubMed.26747099.s1.e2" text="ritonavir" /><entity charOffset="91-101" id="DDI-PubMed.26747099.s1.e3" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e0" e2="DDI-PubMed.26747099.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e0" e2="DDI-PubMed.26747099.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e0" e2="DDI-PubMed.26747099.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e0" e2="DDI-PubMed.26747099.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e1" e2="DDI-PubMed.26747099.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e1" e2="DDI-PubMed.26747099.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e1" e2="DDI-PubMed.26747099.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e2" e2="DDI-PubMed.26747099.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s1.e2" e2="DDI-PubMed.26747099.s1.e3" /></sentence><sentence text="Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4"><entity charOffset="0-11" id="DDI-PubMed.26747099.s2.e0" text="Bedaquiline" /></sentence><sentence text=" Concomitant ART is important for all HIV-infected patients treated for TB, but several antiretrovirals inhibit or induce CYP3A4" /><sentence text=" Single-dose drug-drug interaction studies found no significant interactions with nevirapine or lopinavir/ritonavir, but these findings could be misleading, especially because of bedaquiline's long terminal t1/2"><entity charOffset="82-92" id="DDI-PubMed.26747099.s4.e0" text="nevirapine" /><entity charOffset="96-105" id="DDI-PubMed.26747099.s4.e1" text="lopinavir" /><entity charOffset="106-115" id="DDI-PubMed.26747099.s4.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26747099.s4.e0" e2="DDI-PubMed.26747099.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s4.e0" e2="DDI-PubMed.26747099.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s4.e0" e2="DDI-PubMed.26747099.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s4.e1" e2="DDI-PubMed.26747099.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s4.e1" e2="DDI-PubMed.26747099.s4.e2" /></sentence><sentence text=" We evaluated the effect of nevirapine and lopinavir/ritonavir on bedaquiline exposure"><entity charOffset="28-38" id="DDI-PubMed.26747099.s5.e0" text="nevirapine" /><entity charOffset="43-52" id="DDI-PubMed.26747099.s5.e1" text="lopinavir" /><entity charOffset="53-62" id="DDI-PubMed.26747099.s5.e2" text="ritonavir" /><entity charOffset="66-77" id="DDI-PubMed.26747099.s5.e3" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e0" e2="DDI-PubMed.26747099.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e0" e2="DDI-PubMed.26747099.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e0" e2="DDI-PubMed.26747099.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e0" e2="DDI-PubMed.26747099.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e1" e2="DDI-PubMed.26747099.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e1" e2="DDI-PubMed.26747099.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e1" e2="DDI-PubMed.26747099.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e2" e2="DDI-PubMed.26747099.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s5.e2" e2="DDI-PubMed.26747099.s5.e3" /></sentence><sentence text="" /><sentence text="We conducted a parallel-group pharmacokinetic study of three groups of participants who were on bedaquiline as part of therapy for drug-resistant TB: no ART (HIV seronegative); nevirapine-based ART; and lopinavir/ritonavir-based ART"><entity charOffset="96-107" id="DDI-PubMed.26747099.s7.e0" text="bedaquiline" /><entity charOffset="177-187" id="DDI-PubMed.26747099.s7.e1" text="nevirapine" /><entity charOffset="203-212" id="DDI-PubMed.26747099.s7.e2" text="lopinavir" /><entity charOffset="213-222" id="DDI-PubMed.26747099.s7.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e0" e2="DDI-PubMed.26747099.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e0" e2="DDI-PubMed.26747099.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e0" e2="DDI-PubMed.26747099.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e0" e2="DDI-PubMed.26747099.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e1" e2="DDI-PubMed.26747099.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e1" e2="DDI-PubMed.26747099.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e1" e2="DDI-PubMed.26747099.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e2" e2="DDI-PubMed.26747099.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s7.e2" e2="DDI-PubMed.26747099.s7.e3" /></sentence><sentence text=" Non-compartmental analyses were done and exposure of bedaquiline and its M2 metabolite compared between the no-ART group and the two ART groups"><entity charOffset="54-65" id="DDI-PubMed.26747099.s8.e0" text="bedaquiline" /></sentence><sentence text="" /><sentence text="We enrolled 48 participants: 17 in the no-ART group, 17 in the nevirapine group and 14 in the lopinavir/ritonavir group"><entity charOffset="63-73" id="DDI-PubMed.26747099.s10.e0" text="nevirapine" /><entity charOffset="94-103" id="DDI-PubMed.26747099.s10.e1" text="lopinavir" /><entity charOffset="104-113" id="DDI-PubMed.26747099.s10.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26747099.s10.e0" e2="DDI-PubMed.26747099.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s10.e0" e2="DDI-PubMed.26747099.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s10.e0" e2="DDI-PubMed.26747099.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s10.e1" e2="DDI-PubMed.26747099.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s10.e1" e2="DDI-PubMed.26747099.s10.e2" /></sentence><sentence text=" The following median bedaquiline pharmacokinetic parameters were significantly higher in the lopinavir/ritonavir group than in the no-ART group: AUC(0-48) (67 002 versus 34 730 ng · h/mL; P = 0"><entity charOffset="22-33" id="DDI-PubMed.26747099.s11.e0" text="bedaquiline" /><entity charOffset="94-103" id="DDI-PubMed.26747099.s11.e1" text="lopinavir" /><entity charOffset="104-113" id="DDI-PubMed.26747099.s11.e2" text="ritonavir" /><entity charOffset="132-138" id="DDI-PubMed.26747099.s11.e3" text="no-ART" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e0" e2="DDI-PubMed.26747099.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e0" e2="DDI-PubMed.26747099.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e0" e2="DDI-PubMed.26747099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e0" e2="DDI-PubMed.26747099.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e1" e2="DDI-PubMed.26747099.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e1" e2="DDI-PubMed.26747099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e1" e2="DDI-PubMed.26747099.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e2" e2="DDI-PubMed.26747099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s11.e2" e2="DDI-PubMed.26747099.s11.e3" /></sentence><sentence text="003); Tmax (6 versus 4 h; P = 0" /><sentence text="003); and t1/2 (55 versus 31 h; P = 0" /><sentence text="004)" /><sentence text=" On multivariate analysis, bedaquiline exposure was increased by lopinavir/ritonavir, male sex and time on bedaquiline"><entity charOffset="27-38" id="DDI-PubMed.26747099.s15.e0" text="bedaquiline" /><entity charOffset="65-74" id="DDI-PubMed.26747099.s15.e1" text="lopinavir" /><entity charOffset="75-84" id="DDI-PubMed.26747099.s15.e2" text="ritonavir" /><entity charOffset="107-118" id="DDI-PubMed.26747099.s15.e3" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e0" e2="DDI-PubMed.26747099.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e0" e2="DDI-PubMed.26747099.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e0" e2="DDI-PubMed.26747099.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e0" e2="DDI-PubMed.26747099.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e1" e2="DDI-PubMed.26747099.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e1" e2="DDI-PubMed.26747099.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e1" e2="DDI-PubMed.26747099.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e2" e2="DDI-PubMed.26747099.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s15.e2" e2="DDI-PubMed.26747099.s15.e3" /></sentence><sentence text=" Bedaquiline exposure was not significantly different between the nevirapine group and the no-ART group"><entity charOffset="1-12" id="DDI-PubMed.26747099.s16.e0" text="Bedaquiline" /><entity charOffset="66-76" id="DDI-PubMed.26747099.s16.e1" text="nevirapine" /><entity charOffset="91-97" id="DDI-PubMed.26747099.s16.e2" text="no-ART" /><pair ddi="false" e1="DDI-PubMed.26747099.s16.e0" e2="DDI-PubMed.26747099.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s16.e0" e2="DDI-PubMed.26747099.s16.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s16.e0" e2="DDI-PubMed.26747099.s16.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s16.e1" e2="DDI-PubMed.26747099.s16.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s16.e1" e2="DDI-PubMed.26747099.s16.e2" /></sentence><sentence text=" M2 metabolite exposure was not significantly different in either of the antiretroviral groups compared with the no-ART group"><entity charOffset="113-119" id="DDI-PubMed.26747099.s17.e0" text="no-ART" /></sentence><sentence text="" /><sentence text="Lopinavir/ritonavir significantly increased bedaquiline exposure"><entity charOffset="0-9" id="DDI-PubMed.26747099.s19.e0" text="Lopinavir" /><entity charOffset="10-19" id="DDI-PubMed.26747099.s19.e1" text="ritonavir" /><entity charOffset="44-55" id="DDI-PubMed.26747099.s19.e2" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.26747099.s19.e0" e2="DDI-PubMed.26747099.s19.e0" /><pair ddi="false" e1="DDI-PubMed.26747099.s19.e0" e2="DDI-PubMed.26747099.s19.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s19.e0" e2="DDI-PubMed.26747099.s19.e2" /><pair ddi="false" e1="DDI-PubMed.26747099.s19.e1" e2="DDI-PubMed.26747099.s19.e1" /><pair ddi="false" e1="DDI-PubMed.26747099.s19.e1" e2="DDI-PubMed.26747099.s19.e2" /></sentence><sentence text=" The clinical significance of this interaction remains to be determined" /><sentence text="" /></document>